Table 2.

Tumor response according to the mRECIST.

Characteristic	T+C+L vs T+C	P value	T+C+L vs TACE	P value
CR	9(15.8%) vs 3(7.3%)		9(15.8%) vs 1(2.3%)
PR	24(42.1%) vs 14(34.1%)		24(42.1%) vs 13(30.2%)
SD	10(17.5%) vs 7(17.1%)		10(17.5%) vs 10(23.3%)
PD	14(24.6%) vs 17(41.5%)		14(24.6%) vs 19(44.2%)
ORR	33(57.9%) vs 17(41.5%)	0.108	33(57.9%) vs 14(32.6%)	0.012
DCR	43(75.4%) vs 24(58.5%)	0.076	43(75.4%) vs 24(55.8%)	0.039

Data are presented as n (%). T+L+C, transarterial chemoembolization combined with lenvatinib plus camrelizumab; T+C, transarterial chemoembolization combined with camrelizumab; TACE, transarterial chemoembolization; mRECIST, modified Response Evaluation Criteria In Solid Tumors. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.